Clinuvel Pharmaceuticals Limited cash flow statement CLVLF
In fiscal 2026, which ended Jun 30, 2026, Clinuvel Pharmaceuticals Limited generated $12.9 million of cash from operations. It spent $1.1 million on capital expenditures. That left free cash flow of $11.8 million. The company returned $1.7 million in dividends to shareholders.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
|---|---|
| Operating | |
| Depreciation and amortization |
0
|
| Stock-based compensation |
2
|
| Operating cash flow |
13
|
| Investing | |
| Capital expenditures |
1
|
| Investing cash flow |
-26
|
| Financing | |
| Dividends paid |
2
|
| Financing cash flow |
-2
|
| Change in cash | |
| Net change in cash |
-4
|
| Free cash flow |
12
|
| Per share | |
| Free cash flow per share |
0.23
|
| Shareholder returns | |
| Returned to shareholders |
2
|
| Share of free cash flow |
14.09%
|
| Ratios | |
| Free cash flow margin |
18.42%
|
| Capital expenditures to revenue |
1.64%
|
| Stock-based compensation to revenue |
2.47%
|
| Cash conversion |
0.56x
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- American Depositary Receipts (SIC 8880)
- Listed as
- CUVL (Nasdaq), CLVLF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Melbourne, Victoria
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1290877
- Former names
- EpiTan LTD (until Mar 20, 2006)
Other American Depositary Receipts companies
- Kongsberg Gruppen ASA/ADR KBGGY
- Sumitomo Electric Industries LTD/ADR/ SMTOY
- MTN Group LTD/ADR MTNOY
- Daiwa Securities Group Inc. DSEEY
- Yara International ASA YARIY
- Weir Group PLC/ADR WEGRY
- Pandora A/S / ADR PNDRY
- Vibra Energia S.A./ADR VBREY
Source: SEC EDGAR filings. This is company-reported data, not investment advice.